{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:03:19Z","timestamp":1788386599175,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,9]]},"DOI":"10.7759\/cureus.38767","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T15:20:57Z","timestamp":1683645657000},"source":"Crossref","is-referenced-by-count":1,"title":["Achieving Intraperitoneal Disease Control Using Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Two Cases of Metastatic Breast Cancer"],"prefix":"10.7759","author":[{"given":"Philipp","family":"Barakat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Gushchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Falla Zuniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Caitlin","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.822550","article-title":"Selected patients with peritoneal metastases from breast cancer may benefit from cytoreductive surgery: the results of a multicenter survey","volume":"12","author":"Cardi M","year":"2022","unstructured":"Cardi M, Pocard M, Dico RL, et al.. Selected patients with peritoneal metastases from breast cancer may benefit from cytoreductive surgery: the results of a multicenter survey. Front Oncol. 2022, 12:822550. 10.3389\/fonc.2022.822550","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2013.02.020","article-title":"Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: a preliminary report on 5 cases","volume":"22","author":"Cardi M","year":"2013","unstructured":"Cardi M, Sammartino P, Framarino ML, et al.. Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: a preliminary report on 5 cases. Breast. 2013, 22:845-9. 10.1016\/j.breast.2013.02.020","journal-title":"Breast"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/gs-20-893","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis from breast cancer: a preliminary report of 4 cases","volume":"10","author":"Yu JH","year":"2021","unstructured":"Yu JH, Feng Y, Li XB, et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis from breast cancer: a preliminary report of 4 cases. Gland Surg. 2021, 10:1315-24. 10.21037\/gs-20-893","journal-title":"Gland Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1247-5_3","article-title":"Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration","volume":"82","author":"Sugarbaker PH","year":"1996","unstructured":"Sugarbaker PH, Stuart OA, Vidal-Jove J, Pessagno AM, DeBruijn EA. Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration. Cancer Treat Res. 1996, 82:41-52. 10.1007\/978-1-4613-1247-5_3","journal-title":"Cancer Treat Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5MIR0720-271RR","article-title":"Specialized immune responses in the peritoneal cavity and omentum","volume":"109","author":"Liu M","year":"2021","unstructured":"Liu M, Silva-Sanchez A, Randall TD, Meza-Perez S. Specialized immune responses in the peritoneal cavity and omentum. J Leukoc Biol. 2021, 109:717-29. 10.1002\/JLB.5MIR0720-271RR","journal-title":"J Leukoc Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1449-x","article-title":"Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer","volume":"4","author":"Bertozzi S","year":"2015","unstructured":"Bertozzi S, Londero AP, Cedolini C, et al.. Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer. Springerplus. 2015, 4:688. 10.1186\/s40064-015-1449-x","journal-title":"Springerplus"},{"key":"ref7","article-title":"Expect the unexpected: peritoneal spread--late relapse presentation of breast cancer","volume":"10","author":"Katz D","year":"2008","unstructured":"Katz D, Peretz T, Maly B, et al.. Expect the unexpected: peritoneal spread--late relapse presentation of breast cancer. Isr Med Assoc J. 2008, 10:310-311.","journal-title":"Isr Med Assoc J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.04.027","article-title":"Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis","volume":"45","author":"Tuthill M","year":"2009","unstructured":"Tuthill M, Pell R, Guiliani R, et al.. Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis. Eur J Cancer. 2009, 45:2146-9. 10.1016\/j.ejca.2009.04.027","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.3640","article-title":"Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the American College of Surgeons National Surgical Quality Improvement Program","volume":"149","author":"Jafari MD","year":"2014","unstructured":"Jafari MD, Halabi WJ, Stamos MJ, Nguyen VQ, Carmichael JC, Mills SD, Pigazzi A. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the American College of Surgeons National Surgical Quality Improvement Program. JAMA Surg. 2014, 149:170-5. 10.1001\/jamasurg.2013.3640","journal-title":"JAMA Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0800-0","article-title":"A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin","volume":"63","author":"Van der Speeten K","year":"2009","unstructured":"Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol. 2009, 63:799-805. 10.1007\/s00280-008-0800-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel WJ","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, et al.. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018, 378:230-40. 10.1056\/NEJMoa1708618","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua TC","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, et al.. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012, 30:2449-56. 10.1200\/JCO.2011.39.7166","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment","volume":"47","author":"Govaerts K","year":"2021","unstructured":"Govaerts K, Lurvink RJ, De Hingh IH, et al.. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2021, 47:11-35. 10.1016\/j.ejso.2020.02.012","journal-title":"Eur J Surg Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.05.006","article-title":"Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer","volume":"47","author":"Koole SN","year":"2021","unstructured":"Koole SN, Kieffer JM, Sikorska K, et al.. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer. Eur J Surg Oncol. 2021, 47:101-7. 10.1016\/j.ejso.2019.05.006","journal-title":"Eur J Surg Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2022.33.e54","article-title":"Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)","volume":"33","author":"Kim JH","year":"2022","unstructured":"Kim JH, Lee DE, Lee Y, et al.. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01). J Gynecol Oncol. 2022, 33:e54. 10.3802\/jgo.2022.33.e54","journal-title":"J Gynecol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.11.019","article-title":"Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients","volume":"40","author":"Passot G","year":"2014","unstructured":"Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, Glehen O, Cotte E. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol. 2014, 40:529-35. 10.1016\/j.ejso.2013.11.019","journal-title":"Eur J Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-012-2579-9","article-title":"Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk?","volume":"20","author":"Tsilimparis N","year":"2013","unstructured":"Tsilimparis N, Bockelmann C, Raue W, Menenakos C, Perez S, Rau B, Hartmann J. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk?. Ann Surg Oncol. 2013, 20:226-32. 10.1245\/s10434-012-2579-9","journal-title":"Ann Surg Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/150965-achieving-intraperitoneal-disease-control-using-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-two-cases-of-metastatic-breast-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:03Z","timestamp":1707508743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/150965-achieving-intraperitoneal-disease-control-using-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-two-cases-of-metastatic-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.38767","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}